Formulation development and in vivo evaluation of a new dry powder formulation of albuterol sulphate in beagle dogs

Pharmaceutical Research

Volumn 27, Issue 5, 2010, Pages 894-904

  Kuehl, Philip J ^a   Barrett, Edward G ^a   McDonald, Jacob D ^a   Rudolph, Karin ^a   Vodak, David ^b   Dobry, Dan ^b   Lyon, David ^b  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b Bend Research Incorporated   (United States)

Author keywords

Albuterol; Drug delivery; Inhalation; Novel excipients

Indexed keywords

DEXTRAN 10; EXCIPIENT; SALBUTAMOL SULFATE; UNCLASSIFIED DRUG;

AEROSOL; AIRWAY RESISTANCE; ALLERGY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRONCHODILATING ACTIVITY; BRONCHOSPASM; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DOG; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRY POWDER; GLASS TRANSITION TEMPERATURE; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; LUNG COMPLIANCE; MALE; MAXIMUM PLASMA CONCENTRATION; NEBULIZATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAGWEED; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY DIFFRACTION;

ADSORPTION; AIRWAY RESISTANCE; ALBUTEROL; AMBROSIA; ANIMALS; BRONCHODILATOR AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DESICCATION; DOGS; LASERS; LUNG COMPLIANCE; MALE; MASS SPECTROMETRY; MICROSCOPY, ELECTRON, SCANNING; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; POWDERS; RESPIRATORY HYPERSENSITIVITY; X-RAY DIFFRACTION;

EID: 77953285448     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0084-z     Document Type: Article

References (25)

1. Mogalian E, Myrdal PB, Pharmaceutical solvents for pulmonary drug delivery, solvent systems and their selection in pharmaceutics and biopharmaceutics. New York: Springer; 2007.
2. Arturson G, Wallenius G. The intravascular persistence of dextran of different molecular sizes in normal humans. Scand J Clin Lab Invest. 1964; 16:76-80.
3. Barrowcliffe MP, Zanelli GD, Ellison D, Jones JG. Clearance of charged and uncharged dextrans from normal and injured lung. J Appl Physiol. 1990; 68:341-347 (Pubitemid 20075253)
4. Dubick MA, Wade CE, the HSD Development Group. Evaluation of the local irritation potential of hypertonic salinedextran (HSD) in mice and rabbits. J Appl Toxicol. 2004; 24:409-413
5. Dubick MA, Wade CE. A review of the efficacy and safety of 7.5% NaCl/6% dextran 70 in experimental animals and humans. J Trauma. 1994; 36:323-330
6. PolyDex Pharmaceuticals Limited. Corporate Overview. Supportive Industry Partners, http://www.polydex.com/v2/company/ corporate-overview.html (accessed 02 Feb 2010).
7. Wuillemin WA, te Velthuis HY, Lubbers YT, de Ruig CP, Eldering E, Hack CE. Potentiation, of Cl inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vito complement activation in plasma. J Immunol. 1997; 159:1953-1960
8. Yahata T, Nishimura Y, Maeda H, Yokoyama M. Modulation of airway responsiveness by anionic and cationic polyelectrolyte substances. EurJ Pharmacol. 2002; 434(1-2):71-79 (Pubitemid 34033748)
9. Redman TK, Rudolph K, Barr EB, Bowen LE, Muggenburg BA, Bice DE, Pulmonary immunity to ragweed in a beagle dog model of allergic asthma. Exp Lung Res. 2001; 27:433-451 (Pubitemid 32641829)
10. Barrett EG, Rudolph K, Bowen LE, Muggenburg BA, Bice DE. Effect of inhaled ultrafine carbon particles on the allergic airway response in ragweed sensitized dogs. Inhal Toxicol. 2003; 15:151-165 (Pubitemid 36222336)
11. Barrett EG, Rudolph K, Bowen LE, Bice DE. Parental allergic status influences the risk of developing allergic sensitization and an asthmatic-like phenotype in canine offspring. Immunology 2003; 110:493-500. (Pubitemid 37526691)
12. Doyle-Eisele M, Kuehl PJ, Spindle RW, McDonald JD. Aerosol deposition of inhaled dry powder and nebulized albuterol inbeagle dogs. Presented at AAAR Annual Conference, Minneapolis, MN, (Oct 2009).
13. Bide RW, Armour SJ, Yee E. Allometric respiration/body mass data for animals to be used for estimates of inhalation toxicity to young adult humans. J Appl Toxicol. 2000; 20(4):273-290 (Pubitemid 30601407)
14. Wuillemin WA, Eldering E, Citarella F, de Ruig CP, ten Cate H, Hack CE. Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa. J Biol Chem. 1996; 271:12913-12918 (Pubitemid 26175865)
15. Laumonier T, Walpen AJ, Maurus CF, Mohacsi PJ, Matozan KM, Korchagina EY, et al. Dextran sulfate acts as an endothelial cell protectant and inhibits human complement and natural killer cell-mediated cytotoxicity against porcine cells. Transplantation 2003; 76:838-843 (Pubitemid 37142458)
16. Banz Y, Cung T, Korchagina EY, Bovin NV, Haeberli A, Rieben R. Endothelial cell protection and complement inhibition in xenotransplantation: a novel in vito model using whole blood. Xenotransplantation 2005; 12:434-443
17. Spirig R, van Kooten C, Obregon C, Nicod L, Daha M, Rieben R. The complement inhibitor low molecular weight dextran sulfate prevents TLR4-induced phenotypic and functional maturation of human dendritic cells. J Immunol. 2008; 181 (2):878-890
18. Lukacs NW, Glovsky MM, Ward PA. Complement-dependent immune complex-induced bronchial inflammation and hyper-reactivity. Am J Physiol Lung Cell Mol Physiol. 2001; 280(3): L512-L518.
19. Nilsson G, Johnell M, Hammer CH, Tiffany HL, Nilsson K, Metcalfe DD, et al. C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J Immunol. 1996; 157:1693-1698 (Pubitemid 126449112)
20. Stimler-Gerard NP, Galli SJ. Mast cells are not required for anaphylatoxin-induced ileal smooth muscle contraction. J Immunol. 1987; 138:1908-1913
21. Schellenberg RR, Foster A. In vitro responses of human asthmatic airway and pulmonary vascular smooth muscle. Int Arch Allergy Appl Immunol. 1984; 75:237-241
22. Stimler NP, Hugli TE, Bloor CM. Pulmonary injury induced by C3a and C5a anaphylatoxins. Am J Pathol. 1980; 100:327-338
23. Baelder R, Fuchs B, Bautsch W, Zwirner J, Kohl J, Hoymann HG, et al. Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation, J Immunol. 2005; 174(2):783-789 (Pubitemid 40094273)
24. Mizutani N, Nabe T, Yoshino S. Complement C3a regulates late asthmatic response and airway hyperresponsiveness in mice. J Immunol. 2009; 183:4039-4046
25. Nakano Y, Morita S, Kawamoto A, Suda T, Chida K, Nakamura H. Elevated complement C3a in plasma from patients with severe acute asthma. J Allergy Clin Immunol. 2003; 112(3):525-530 (Pubitemid 37108556)